What is FIRAZYR?

Put the power of portable treatment in your patient's hands

Not a real patient.

Here you'll learn important information about FIRAZYR, the first prefilled, self-administered, subcutaneous injection to treat acute HAE attacks of HAE in adults 18 years or older.1

Efficacy

FIRAZYR can be used to treat all types of acute HAE attacks: cutaneous, abdominal, and laryngeal.1

See cutaneous and abdominal attack study results »
See laryngeal and multiple attack study results »

FIRAZYR Safety Profile

See warnings and precautions, adverse reactions, drug interactions, and other important information you should know about FIRAZYR.

Review safety profile »

Bradykinin and The FIRAZYR MOA

FIRAZYR inhibits bradykinin from binding to the B2 receptor and thereby treats the clinical symptoms of an acute, episodic attack of HAE.1

Learn about how FIRAZYR works »

Dosing & Administration

Patients may self-administer FIRAZYR upon recognition of symptoms of an HAE attack, after training by a healthcare professional.1

Learn more about dosing and administration »

Role of Acute Therapy

FIRAZYR can help ensure your patients are prepared in case of an attack.

Learn more about the role acute therapy can play »